Month: April 2025

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD’s virtual care platform. LifeMD’s weight management program is one of the fastest-growing cash-pay offerings in the country, delivering virtual consultations, lab testing, diet and lifestyle support, and prescriptions to anti-obesity medications including GLP-1s when clinically appropriate, within a single, tech-enabled platform. The addition of direct access to Wegovy® through NovoCare® Pharmacy enhances LifeMD’s ability to support patients with...

Study supported by the Michael J. Fox Foundation through a grant awarded to ZyVersa and leading inflammasome experts at University of Miami Miller School of Medicine who conducted the study. Parkinson’s Disease (PD) affects over 10 million people globally and is driven by inflammation leading to progressive neurodegeneration resulting in impaired mobility, cognitive decline, and other neurological symptoms. Abnormal alpha-synuclein accumulation/aggregation and inflammasome activation are key contributors to PD progression; targeting both may help slow or halt disease advancement. Current PD treatments address only symptoms—not the underlying disease; the global PD drug market was valued at $6.6 billion in 2024 and is projected to reach $13.3 billion by 2034 (Precedence Research).WESTON, Fla., April 29, 2025 (GLOBE NEWSWIRE) —...

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atrophy (Phase 2 ArMaDa clinical trial), at The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah from May 4-8, 2025, and Retina World Congress at the Marriott Harbor Beach Resort in Ft. Lauderdale, Florida from May 8-11,...

ATLANTA, April 29, 2025 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the RBC 2025 Global Healthcare Conference in New York on May 20, 2025. Management will host 1×1 investor meetings as well as a fireside chat at 11:30 a.m. Eastern Time on the same day, May 20, 2025. Interested investors and other parties may also listen to a simultaneous webcast of the presentation by logging onto the Investor Relations section of the Company’s website at https://ir.aveanna.com/. The online replay will be available for a limited time shortly following the call. About Aveanna Healthcare Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 34 states providing a broad range of pediatric and adult healthcare services including nursing,...

Vilnius, Lithuania, April 29, 2025 (GLOBE NEWSWIRE) — AB Tewox (the Company) publishes its audited annual consolidated and separate financial statements for 2024 together with Company’s and Group’s annual management report for 2024. Financial results The objective of the Company is to earn a return to shareholders through investments in individual income-generating real estate objects – either under development or already developed – intended for retail or other (commercial and/or residential) purposes in the Baltic Sea Region countries – Lithuania, Latvia, Estonia, Finland, Sweden, Denmark, Poland and Germany. The main financial indicators for the period were:As at 31 December 2024, the Company’s total assets were EUR 75,648 thousand, total equity was EUR 43,448 thousand, and total liabilities were EUR 32,200 thousand. As at...

–Company reports record revenue of $17.6 million for FY 2024, an increase of 21% – –Company to host conference call Today, Tuesday, April 29th at 11am ET/8am PT –NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICESCARLSBAD, Calif., April 29, 2025 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal surgery outcomes, today announced its financial results for fourth quarter and fiscal year ended December 31, 2024.All figures are in U.S. dollars.Financial and Business HighlightsRecord quarterly and annual revenue – The company recorded its largest ever fourth quarter revenue of $4,702,317 in Q4 2024 compared to Q4 2023 sales of $4,044,234 an improvement of...

VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces today it will showcase its ZenaDrone 1000 and IQ series drones as an exhibitor at several prominent upcoming US defense and technology conferences starting this week. These events will be an important opportunity to engage one-on-one with potential customers, key stakeholders, and industry leaders across the US military and government sectors as well as in the mining sector. Conference Details: Modern Day Marine: Recognized as the largest military equipment, systems, services, and technology expositions exclusively targeted to Marine...

– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health – TORONTO, April 29, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce initial perioperative data from the Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA procedure with radical prostatectomy (“RP”) in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. The positive perioperative...